PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2019
CASE
AUTH/3254/10/19 Napp Pharmaceuticals

Napp breach over BMJ hosted β€œInvokana” panel: promotional teaser lacked prescribing information link (AUTH/3254/10/19)

A BMJ hosted β€œpanel” for Invokana was ruled promotional (including hover pop-up) and breached Clause 4.1 because it lacked a clear, prominent…

2010
CASE
AUTH/2350/8/10 Pharmacosmos

AUTH/2350/8/10: Vifor Pharma v Pharmacosmos – β€œbest-in-class”, β€œnovel treatment” and hanging comparison for Monofer

Pharmacosmos’ UK-facing website announcement implied Monofer was β€œbest-in-class”, called it β€œnovel”, and used a β€œmore patients” one-visit repletion claim without stating the…

2010
CASE
AUTH/2370/11/10 Sanofi

AUTH/2370/11/10: Anonymous employee v Sanofi-Aventis (alleged excessive hospitality at overseas meetings) – No breach

Anonymous employee alleged excessive hospitality and alcohol at Paris (2009) and San Francisco (2010) meetings. Panel criticised poor records but found no…

2011
CASE
AUTH/2393/3/11 Baxter Healthcare

Baxter voluntary admission: reps failed to take ABPI exam within first year (AUTH/2393/3/11)

Baxter admitted some representatives had not taken the ABPI Medical Representatives Examination within their first year. The PMCPA ruled a breach of…

2011
CASE
AUTH/2380/1/11 Allergan ⭐ Case of the Week

AUTH/2380/1/11: Merz Pharma v Allergan β€” β€œNo set dose ratio” claim on Botox exhibition panel (No breach)

Merz challenged Allergan’s National Stroke Forum panel claiming β€œNo set dose ratio…”. Panel found the claim reflected SPCs and wasn’t misleading; also…

2018
CASE
AUTH/3085/9/18 Biogen

AUTH/3085/9/18: Director v Biogen β€” Clinical trial disclosure (EUCTR) β€” No breach

BMJ EU Trials Tracker data suggested Biogen had 3 β€œdue” EUCTR trials without posted results. Panel found 2 had no participants (no…

2011
CASE
AUTH/2454/11/11 Celgene

AUTH/2454/11/11: Pharmacist v Celgene β€” advisory board honoraria alleged as disguised promotion (No breach)

A hospital pharmacist alleged Celgene used Vidaza advisory boards and Β£600 honoraria as disguised promotion/inducement around SMC timing. PMCPA found the meetings…

2018
CASE
AUTH/3071/9/18 Novo Nordisk

AUTH/3071/9/18: Director v Novo Nordisk (clinical trial disclosure) – No breach

PMCPA reviewed an alleged failure to post EUCTR results for one Novo Nordisk trial flagged by a BMJ audit. Trial was withdrawn…

2018
CASE
AUTH/3092/9/18 Celgene

AUTH/3092/9/18 – Director v Celgene (Outwith scope of the Code; no breach)

PMCPA case AUTH/3092/9/18 (Director v Celgene) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…

2018
CASE
AUTH/3072/9/18 Servier ⭐ Case of the Week

AUTH/3072/9/18: Director v Servier β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3072/9/18 (Director v Servier) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…

2012
CASE
AUTH/2504/5/12 Sanofi

Sanofi: anonymous ex-employee allegations about medical team contact targets, unlicensed promotion and NICE/CDF lobbying (AUTH/2504/5/12) – no breach

Anonymous ex-employee alleged medical oncology staff were pressured to generate proactive contacts, promote unlicensed medicines, exceed call limits and solicit NICE challenge…

2012
CASE
AUTH/2492/3/12 Meda Pharmaceuticals

Meda Pharmaceuticals: EpiPen booklet claims ruled misleading and unprofessional (AUTH/2492/3/12)

A prescribing advisor challenged Meda’s β€˜Case for EpiPen’ booklet as emotive and unsubstantiated. The PMCPA ruled multiple claims misleading/unsubstantiated and one statement…

2008
CASE
Bayer

Bayer voluntary admission: uncertified Levitra symposium invitation sent to UK recipients (transparent envelope, missing PI, unapproved strapline)

Bayer self-reported a global-issued Levitra symposium invitation sent to UK delegates without UK certification. It lacked required prescribing/AE info, used an unapproved…

2012
CASE
AUTH/2537/10/12 Bayer

AUTH/2537/10/12: Anonymous v Bayer – Xarelto ad claim β€œone tablet, once daily, simple” (No breach)

Anonymous complaint said a Xarelto GP ad calling dosing β€œsimple” downplayed anticoagulant risks. PMCPA ruled β€œsimple” referred only to once-daily dosing and…

2012
CASE
AUTH/2569/12/12 Novo Nordisk ⭐ Case of the Week

Novo Nordisk detail aid for Victoza: composite endpoint design ruled misleading (AUTH/2569/12/12)

MSD challenged a Victoza detail aid using a β€œtriple composite endpoint” shown in prominent red boxes. PMCPA ruled the presentation misleading (Clause…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training